EP 1253926 A1 20021106 - COMPOUNDS USEFUL FOR THE TREATMENT OR PREVENTION OF A DISEASE MEDIATED BY THE ALPHA-2B-ADRENOCEPTOR
Title (en)
COMPOUNDS USEFUL FOR THE TREATMENT OR PREVENTION OF A DISEASE MEDIATED BY THE ALPHA-2B-ADRENOCEPTOR
Title (de)
VERBINDUNGEN DIE ZUR BEHANDLUNG UND PROPHYLAXE VON DURCH ALPHA-2B-ADRENOZEPTOR VERMITTELTEN ERKRANKUNGEN NÜTZLICH SIND
Title (fr)
COMPOSE UTILE POUR LE TRAITEMENT OU LA PREVENTION D'UNE MALADIE MEDIEE PAR LE RECEPTEUR ADRENERGIQUE ALPHA 2B
Publication
Application
Priority
- FI 0100105 W 20010207
- FI 20000303 A 20000214
- US 18202100 P 20000211
Abstract (en)
[origin: WO0158454A1] The present invention relates to the use of a selective alpha-2B-adrenoceptor antagonist for the manufacture of a pharmaceutical preparation useful for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor in a mammal. Said antagonist is a compound selected from the group consisting of compounds A, B, C, D and E disclosed in Scheme I, or a pharmaceutically acceptable salt of said compound. The present invention also relates to a method for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor in a mammal. Said method comprises administering to said mammal an effective amount of said selective alpha-2B-adrenoceptor antagonist.
IPC 1-7
IPC 8 full level
A61K 31/505 (2006.01); A61K 31/635 (2006.01); A61K 45/06 (2006.01); A61P 3/04 (2006.01); A61P 9/10 (2006.01); A61K 31/506 (2006.01); A61P 9/12 (2006.01); A61P 15/10 (2006.01); A61P 25/06 (2006.01); C07D 239/42 (2006.01); C07D 403/12 (2006.01)
CPC (source: EP KR)
A61K 31/63 (2013.01 - KR); A61K 31/635 (2013.01 - EP); A61K 45/06 (2013.01 - EP); A61P 3/04 (2018.01 - EP); A61P 9/10 (2018.01 - EP); A61P 9/12 (2018.01 - EP); A61P 15/10 (2018.01 - EP); A61P 25/06 (2018.01 - EP); C07D 239/42 (2013.01 - EP); C07D 403/12 (2013.01 - EP)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 0158454 A1 20010816; AU 3551001 A 20010820; AU 780802 B2 20050421; BR 0108221 A 20030305; CA 2399421 A1 20010816; CZ 20022884 A3 20030212; EA 200200846 A1 20021226; EE 200200435 A 20031215; EP 1253926 A1 20021106; GE P20043356 B 20040413; HR P20020746 A2 20041231; HU P0300032 A2 20030528; HU P0300032 A3 20060130; IL 151017 A0 20030212; IS 6476 A 20020719; JP 2003522148 A 20030722; KR 20020080413 A 20021023; MX PA02007454 A 20040823; MY 133957 A 20071130; NO 20023773 D0 20020809; NO 20023773 L 20020809; NZ 520500 A 20050128; PL 357872 A1 20040726; SK 11472002 A3 20030204; YU 59102 A 20051128
DOCDB simple family (application)
FI 0100105 W 20010207; AU 3551001 A 20010207; BR 0108221 A 20010207; CA 2399421 A 20010207; CZ 20022884 A 20010207; EA 200200846 A 20010207; EE P200200435 A 20010207; EP 01907585 A 20010207; GE AP2001004893 A 20010207; HR P20020746 A 20020911; HU P0300032 A 20010207; IL 15101701 A 20010207; IS 6476 A 20020719; JP 2001557564 A 20010207; KR 20027010329 A 20020809; MX PA02007454 A 20010207; MY PI20010579 A 20010209; NO 20023773 A 20020809; NZ 52050001 A 20010207; PL 35787201 A 20010207; SK 11472002 A 20010207; YU P59102 A 20010207